eCite Digital Repository

Successful add-on viloxazine to clozapine-responsive schizophrenia mitigated cognitive, negative and metabolic domains

Citation

Naguy, A and Rushdy, R and Pridmore, S and Singe, A and Alamiri, B, Successful add-on viloxazine to clozapine-responsive schizophrenia mitigated cognitive, negative and metabolic domains, Psychopharmacology Bulletin, 52, (1) pp. 57-60. ISSN 2472-2448 (2022) [Contribution to Refereed Journal]


Preview
PDF
Pending copyright assessment - Request a copy
174Kb
  

Official URL: https://europepmc.org/article/med/35342203

Abstract

Early-onset schizophrenia is notorious for poor prognostication and treatment-refractoriness. Clozapine remains a viable option, albeit off-label, but is clearly underutilized in this population. Use is typically fraught with panoply of drastic side effects. Here, authors report on an adolescent case with schizophrenia that responded ultimately to clozapine. Add-on viloxazine was advantageous spanning different symptom domains, mitigating metabolic parameters and addressing clozapine-sialorrhea. This might open new venues for such complicated, yet commonplace, clinical scenarios.

Item Details

Item Type:Contribution to Refereed Journal
Keywords:schizophrenia, treatment-refractoriness, clozapine, viloxazine, sialorrhea
Research Division:Biomedical and Clinical Sciences
Research Group:Pharmacology and pharmaceutical sciences
Research Field:Clinical pharmacology and therapeutics
Objective Division:Manufacturing
Objective Group:Human pharmaceutical products
Objective Field:Human pharmaceutical treatments
UTAS Author:Pridmore, S (Professor Saxby Pridmore)
ID Code:150820
Year Published:2022
Deposited By:Medicine
Deposited On:2022-07-01
Last Modified:2022-07-01
Downloads:0

Repository Staff Only: item control page